Charles A Dinarello

This inventor holds 45 USPTO granted patents and 30 published patent applications, plus 6 CIPO patents and 12 EPO patents, primarily in Cancer Treatment. Top assignees: University of Colorado, Yeda Research and Develpment & Co. Ltd, Olatec Therapeutics LLC. Active years: 1984-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles A Dinarello. Retrieved from https://idiyas.com/inventor/charles-a-dinarello

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 45 (Patent Applications = 30)

% Patents Active = 62.2

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 190(Granted Patents)

Location History:

Boston, MA (US) (1984 - 1991)
Suffolk, MA (US) (1999)
Boulder, CO (US) (1999 - 2024)
Denver, CO (US) (2012 - 2024)

Company Filing History:

16 out of 1,453

University of Colorado

patents

8 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

7 out of 31

Olatec Therapeutics LLC

Konkuk University Industry Cooperation Foundation

patents

8. 3 out of 97

New England Medical Center Hospitals. Inc.

patents

9. 3 out of 16

Senesco Technologies, Inc.

Massachusetts Institute of Technology

patents

12. 1 out of 365

Ben-Gurion University of the Negev Research and Development Authority

patents

13. 1 out of 12

Bio-Techne Corporation

New England Medical Center

patents

16. 1 out of 420

Virginia Commonwealth University

patents

17. 2 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 1984-2026

Loading Chart...

Areas of Expertise:

Breast Cancer

Diabetes

Cardiovascular Diseases

Melanoma

Alzheimer's Disease

Alpha-1 Antitrypsin

Tumor Necrosis Factor-alpha

Sepsis

Interleukin-18

Graft Versus Host Disease

Cytokine Therapy

Apoptosis Modulation

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582628 - METHODS FOR TREATING BREAST CANCER (2026-03-24),

2. 12569463 - Method for treating diabetes (2026-03-10),

3. 12318361 - Methods for treating cardiovascular diseases (2025-06-03),

4. 12030958 - Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides (2024-07-09),

5. 11857529 - Methods for treating melanoma (2024-01-02),

6. 11576888 - Methods for treating cardiovascular diseases (2023-02-14),

7. 11524985 - IL-37 fusion protein and methods of making and using same (2022-12-13),

8. 11517554 - Method for preventing or treating Alzheimer's disease (2022-12-06),

9. 10723784 - Compositions and methods for preparing a subject for organ or non-organ implantation (2020-07-28),

10. 10548870 - Method for treating multiple sclerosis (2020-02-04),

11. 10478508 - Compositions, methods and uses for alpha-1 antitrypsin fusion molecules (2019-11-19),

12. 10450384 - Compositions of alpha-1 antitrypsin fusion molecules (2019-10-22),

13. 9938353 - Compositions, methods and uses for alpha-1 antitrypsin fusion molecules (2018-04-10),

14. 9895420 - IL-1beta propeptide and IL-1Ra chimera and methods of using the same (2018-02-20),

15. 9884096 - Compositions and methods related to graft versus host disease and treatments thereof (2018-02-06),

Title: Charles A. Dinarello - Pioneering Inventor from Boulder, CO

Introduction: Charles A. Dinarello is a renowned inventor based in Boulder, Colorado, known for his groundbreaking contributions to the field of medical research and biotechnology.

Latest Patents: Charles A. Dinarello holds several patents related to novel pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune disorders.

Career Highlights: With a distinguished career spanning several decades, Dinarello has made significant advancements in understanding the role of cytokines in inflammatory responses, leading to the development of innovative therapies.

Collaborations: Throughout his career, Charles A. Dinarello has collaborated with leading researchers, pharmaceutical companies, and academic institutions to further the field of immunology and drug development.

Conclusion: Charles A. Dinarello's pioneering work continues to have a profound impact on the medical and scientific communities, shaping the future of healthcare and biotechnology.

Profile summary based on public USPTO records.